POLYSTART

Welcome to the Brand page for “POLYSTART”, which is offered here for Chimeric nucleic acid vector delivery systems administered in vivo or ex vivo to evaluate or elevate the expression of an encoded polypeptide or selected antigenic epitopes for medical purposes; chimeric nucleic acid administered in vivo or ex vivo to evaluate or elevate the expression of an encoded polypeptide or selected antigenic epitopes for medical purposes; chimeric nucleic acid-based immunotherapeutic and immunoprophylactic vaccines for the treatment of cancer and infectious disease; vaccine adjuvants;chimeric nucleic acid and nucleic acid molecules for scientific use, research and development use and for use in the manufacture of pharmaceuticals; chimeric nucleic acid and nucleic acid molecules for use in the manufacture of recombinant nucleic acids and recombinant polypeptides/proteins/antigenic determinants encoded thereby;medical and scientific research and development services in the field of vaccine technology specific to oncology or infectious diseases; medical and scientific research and development services in the field of vaccine technology; medical and scientific research and development services in the fields of nucleic acid expression technology, and evaluation of expressed protein, polypeptide, or antigenic epitopes; consulting services in the field of protein expression, vaccine technology, and the elevation of the expression of selected proteins, polypeptides and antigenic epitopes;.

Its status is currently believed to be active. Its class is unavailable. “POLYSTART” is believed to be currently owned by “Marker Therapeutics, Inc.”